The race in biosimilar development is becoming more competitive – and crucial – by the day. The National Center for Biotechnology Information estimates that $100 billion (USD) in biologic drug sales will lose patent protection by 2020.

This projection, combined with global public healthcare budget cuts and advances in biologic manufacturing technology, is creating an intensely competitive marketplace.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Biosimilar drug development presents a host of challenges – constantly evolving global regulatory pathways, and the necessary optimisation of clinical development plans in order to not only gain approval, but to also achieve the ultimate goal of gaining market share.

This article focuses on one specific aspect of biosimilar development: How do we access the reference drug?

 

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

*To finish reading this excellent whitepaper, visit Myoderm’s storefront page here

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact